

Tanzania Support for Human Papillomavirus Vaccine (HPV) Demonstration Programme

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Tanzania									
2. Vaccines grant number: 16-TZA-19b-X									
3. Date of Decision Letter: 10 May 2016									
4. Date of the Partnership Framework Agreement: 1 st July 2013									
5. Programme title: HPV Demonstration Programme									
6. Vaccine type: HPV									
7. Preferred product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID									
8. Programme duration ¹ : 2016 (Extension of support for year 3 before national introduction)									
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable):									
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 20%;">2016²</th> <th style="width: 20%;">Total³</th> </tr> </thead> <tbody> <tr> <td>HPV vaccines (US\$)</td> <td style="text-align: center;">US\$197,000</td> <td style="text-align: center;">US\$197,000</td> </tr> <tr> <td>Total programme Budget (US\$)</td> <td style="text-align: center;">US\$197,000</td> <td style="text-align: center;">US\$197,000</td> </tr> </tbody> </table>		2016 ²	Total ³	HPV vaccines (US\$)	US\$197,000	US\$197,000	Total programme Budget (US\$)	US\$197,000	US\$197,000
	2016 ²	Total ³							
HPV vaccines (US\$)	US\$197,000	US\$197,000							
Total programme Budget (US\$)	US\$197,000	US\$197,000							
10. Vaccine introduction grant: Not applicable									

¹ This is the entire duration of the Programme.

² An extension of support for a third year is granted to countries on the following conditions: (a) the country has completed Year 2; (b) the country has expressed its interest to apply for national HPV vaccine introduction in the immediately following year; and (c) the country needs to continue vaccinating in demonstration districts during the national application review time. The extension of support for Year 3 only provides vaccines (not cash support).

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

Vaccines:

Type of supplies to be purchased with Gavi funds in each year	2016
Number of HPV vaccines doses	42,200
Number of AD syringes	44,300
Number of safety boxes	500
Annual Amounts (US\$)	US\$197,000

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns: Not applicable

16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts. Further details can be found in the HPV application guidelines.

Reports, documents and other deliverables	Due dates
<ol style="list-style-type: none"> 1. A copy of the approval by the local ethics committee, <i>if a country determined that review and approval was required.</i> 2. Three evaluation reports of the HPV vaccination demonstration programme: <ol style="list-style-type: none"> a. Post Introduction Evaluation (PIE) b. Coverage survey c. Costing analysis 3. A report of the assessment of adolescent health interventions, with conclusions about what interventions would be feasible for integration in year 2 <ol style="list-style-type: none"> a. If an adolescent health intervention is identified for joint delivery with HPV vaccine, the report should describe the identified intervention, the modified plans for Year 2, and the steps required for implementation with the district(s) and staff involved. b. If NO adolescent health intervention is identified for joint delivery with HPV vaccine the report should mention the reason why not. 4. A summary of the activities completed and progress towards the development of a national cervical cancer prevention and control strategy. 	Before national application

⁴ This is the amount that Gavi has approved.

5. A financial and activity report of expenditures by the end of year 1.	Immediately
1. If an adolescent health intervention is identified for joint delivery with HPV vaccine OR if the country substantially changed their delivery strategy: <ul style="list-style-type: none"> a. A new survey to measure the coverage of HPV vaccination and the coverage of the jointly delivered health intervention(s) and b. An updated micro-costing analysis of programme delivery costs. (Annex B) 2. If NO adolescent health intervention is identified for joint delivery with HPV vaccine in Year 2: A summary report of year 2 delivery of HPV vaccinations 3. A financial and activity report of expenditures in year 2. 4. A copy of the developed or revised national cervical cancer prevention and control strategy.	Before national application
17. Financial clarifications: Country shall provide the following clarifications to Gavi*: A financial and activity report of expenditures by the end of year 1.	
18. Other conditions: Not applicable	

Signed by,

FOR : **On behalf of Gavi**
Hind Khatib-Othman
Managing Director, Country Programmes
10 May 2016


Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance